RNA and oligonucleotide therapies at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
25 organizations at ESGCT 2026 present work in RNA and oligonucleotide therapies: 14 universities and research institutes, 6 suppliers and service providers, 4 drug developers and 1 agency, society or charity. Between them they bring 124 presentations to the program. Most represented: University College London, CIMA University of Navarra and Tigem. As of Oct 16, 2026.
Format
Top represented
Showing 1–2 of 25 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
University College London London, UK | |
London university with a large gene and cell therapy programme spanning AAV and lentiviral gene therapy, haemophilia and CAR-T trials. | Chair Tue Oct 27 9:30am–11:00am CLINICAL TRIALS AND COMMERCIALISATION WORKSHOP 1 Manufacturing, CMC and accessClinical trials and translation Workshop Tue Oct 27 9:55am–10:45am VLPs for in vivo CAR-T cells Vectors and delivery (AAV, lentiviral, LNP)Cell therapies and CAR-T Chair Tue Oct 27 11:15am–1:00pm CLINICAL TRIALS AND COMMERCIALISATION WORKSHOP 2 Manufacturing, CMC and access Chair Wed Oct 28 8:30am–10:30am SESSION 3b: Hematopoietic & PID Rare and inherited disease Talk Wed Oct 28 9:30am–10:30am Patient-specific gene editing approaches rescue B cell development in X-linked agammaglobulinemia Gene and epigenome editingRare and inherited disease Chair Wed Oct 28 11:00am–12:30pm SESSION 4c: Immunotherapy and CAR T cells II Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm BREAKING FREE FROM VIRUSES: TOWARD A SCALABLE NON-VIRAL PLATFORM FOR HSC GENE THERAPY Poster Wed Oct 28 1:30pm–3:30pm Combinatorial CRISPR-activation Gene Therapy to Treat Intractable Epilepsy Poster Wed Oct 28 1:30pm–3:30pm Developing a 3D in vitro model of skeletal muscle involvement in late-onset Pompe disease for CRISPR-based therapy testing Poster Wed Oct 28 1:30pm–3:30pm Development of in vitro transcribed mRNA therapeutics for cystic fibrosis combined with CFTR modulators. Poster Wed Oct 28 1:30pm–3:30pm Improving the gene therapy vector and applying lipidomics to monitor the efficacy of therapy for CLN3 disease. Poster Wed Oct 28 1:30pm–3:30pm Restoration of cilia motility via mRNA therapy in Primary Ciliary Dyskinesia Poster Wed Oct 28 1:30pm–3:30pm The Development of a PEG-bPEI Nanogel-based Delivery System for Nucleic Acids Chair Wed Oct 28 6:00pm–7:00pm SESSION 6: Gene editing Gene and epigenome editing Chair Thu Oct 29 8:30am–10:30am SESSION 7c: Accessibility of GT Manufacturing, CMC and access Talk Thu Oct 29 8:30am–10:30am SESSION 7d: Skin, pulmonary and skeletal diseases Rare and inherited disease Talk Thu Oct 29 12:30pm–1:00pm Prime Time for patients with metabolic diseases Gene and epigenome editingRare and inherited disease Poster Thu Oct 29 2:00pm–4:00pm A two-in-one AAV donor strategy for manufacturing IMiD-switchable anti-B7H3 CAR T cells Poster Thu Oct 29 2:00pm–4:00pm Cleavage-competent sgRNA contaminants and enhanced off-target detection revealed by DNA repair inhibition in genome-edited HSPCs Poster Thu Oct 29 2:00pm–4:00pm Cryo-EM analysis of viral vector heterogeneity Poster Thu Oct 29 2:00pm–4:00pm Mutation, exon or gene; Trade-offs between correction and cell function for different scales of non-viral HDRT ex vivo correction of XLA. Poster Thu Oct 29 2:00pm–4:00pm Rational design AAV capsid engineering for fibroblast-directed targeting towards Collagen VI muscular dystrophy genetic therapies. Chair Fri Oct 30 9:00am–10:30am SESSION 11b: Bleeding disorders Rare and inherited disease Talk Fri Oct 30 9:10am–10:30am Gene therapy in hemophilia Rare and inherited diseaseClinical trials and translation Talk Fri Oct 30 12:00pm–1:00pm A human multi-organoid framework to improve preclinical assessment of AAV gene therapy in neuromuscular disease Vectors and delivery (AAV, lentiviral, LNP)Rare and inherited disease Talk Fri Oct 30 12:15pm–1:00pm Targeted lipid nanocomplex delivery of angiopoietin-1 mRNA slows progression of childhood kidney disease Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies |
CIMA University of Navarra Pamplona, Spain | |
University of Navarra's applied medical research centre, with gene therapy programs on viral vectors for liver, rare and neurodegenerative diseases. | Chair Tue Oct 27 9:00am–10:45am EDUCATION SESSION 1b - Therapeutic strategies expanding the horizons of GT Cell therapies and CAR-TGene and epigenome editing Workshop Tue Oct 27 11:40am–1:00pm Side effects and protein stress response Clinical trials and translation Chair Tue Oct 27 5:00pm–7:30pm SESSION 2d: Metabolic diseases I In collaboration with JSGCT and CSGCT Rare and inherited disease Talk Tue Oct 27 6:00pm–7:30pm Molecular mechanism of severe hepatotoxicity following high-dose ssAAV9.CBA.SMN1 administration in neonatal mice Vectors and delivery (AAV, lentiviral, LNP)Rare and inherited disease Chair Wed Oct 28 8:30am–10:30am SESSION 3a: AAVs/non integrative vectors II - Technology Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 9:30am–10:30am Preliminary results of a phase I trial evaluating DNX-2440 oncolytic adenovirus in recurrent glioblastoma Cancer gene and cell therapyClinical trials and translation Talk Wed Oct 28 12:00pm–12:30pm Poster Wed Oct 28 1:30pm–3:30pm Cross-species AAV capsid screening identifies non-sensory cochlear vectors for GJB2-related hearing loss gene therapy Poster Wed Oct 28 1:30pm–3:30pm Distinguishing real AAV-mediated renal transduction from proximal tubule protein reabsorption: implications for the assessment of renal gene therapy Poster Wed Oct 28 1:30pm–3:30pm Framework-region charge optimization enhances the anti-tumor potency of CAR-T cells across multiple solid tumors by calibrating tonic signal Poster Wed Oct 28 1:30pm–3:30pm Impact of Radiotherapy on Tumor—CAR-T Cell Interaction Poster Wed Oct 28 1:30pm–3:30pm NKG7 and CMC1 as key mediators underlying clonal expansions in BCMA CAR-T cells Poster Wed Oct 28 1:30pm–3:30pm Rapid and dynamic reprogramming within the tumor microenvironment drives EDA-CAR-T dysfunction and compromised therapeutic efficacy in solid tumors Poster Wed Oct 28 1:30pm–3:30pm Rational design of immunomodulatory peptide display strategies for inducing anti-AAV immune tolerance Poster Wed Oct 28 1:30pm–3:30pm Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple Myeloma Poster Wed Oct 28 1:30pm–3:30pm Retroureteral delivery of engineered AAV capsids drives robust and widespread renal epithelial transduction Chair Wed Oct 28 3:30pm–5:30pm SESSION 5: In vivo gene therapy Vectors and delivery (AAV, lentiviral, LNP) Talk Thu Oct 29 9:00am–10:30am Leveraging immune recognition for developing safer and more potent AAV-based gene therapies Vectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm A synergistic neurohepatic promoter enables single-AAV correction of mitochondrial function in COXPD1 Poster Thu Oct 29 2:00pm–4:00pm Beyond Sensitivity: Intermediate Functional Avidity Drives Superior In Vivo Antitumor Efficacy in TCR-Engineered T Cells Poster Thu Oct 29 2:00pm–4:00pm Generation and characterization of BCMA-targeting humanized scFv-based CAR-T cells for multiple myeloma Poster Thu Oct 29 2:00pm–4:00pm Inhibiting DNA-PK minimizes unwanted rAAV integration during CRISPR-Cas9 editing in vivo Poster Thu Oct 29 2:00pm–4:00pm Novel HER2-Specific sdAb-CAR-T Cells Exhibit Enhanced Antitumoral Efficacy in HER2-Positive Cancers Poster Thu Oct 29 2:00pm–4:00pm Single-cell multiomic profiling defines molecular signatures of human long-term hematopoietic stem cells for next generation gene therapy applications Cell therapies and CAR-T Poster Thu Oct 29 2:00pm–4:00pm Type I interferon-driven mechanisms underlying the therapeutic synergy of CAR-T cells and Semliki Forest virus-based companion vaccines for solid tumor therapy Poster Thu Oct 29 2:00pm–4:00pm Uncovering key regulators of CAR-T cell senescence via immune phenotyping and integrated CRISPR screens Chair Thu Oct 29 6:30pm–7:30pm SESSION 10: Enabling technologies Manufacturing, CMC and access Talk Fri Oct 30 12:45pm–1:00pm Comparative study of viral and non-viral delivery systems for cytokine-expressing self-amplifying RNA in cancer therapy RNA and oligonucleotide therapiesCancer gene and cell therapy |
Instantly find 20 buyers in RNA and oligonucleotide therapies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction